Statin-induced autoimmune hepatitis in patients with type 1 diabetes: A report of two cases and literature review.
Eiji KawasakiTakahiro FukuyamaErisa KuriyamaAira UchidaYoko SagaraHidekazu TamaiYuko NakanoMasayuki TojikuboNobuhiko KogaPublished in: Journal of diabetes investigation (2020)
Statins are widely used medications for the treatment of hypercholesterolemia, as well as prevention of cardiovascular disease. We report two patients with type 1 diabetes who developed autoimmune hepatitis after the administration of statin. The first patient developed the marked elevation of liver enzymes 6 months into atorvastatin therapy. The second patient developed liver dysfunction 8 months after the initiation of rosuvastatin therapy. Liver biopsies in both patients showed either portal, interface and lobular hepatitis or a piece-meal necrosis with lymphocytes and plasma cell infiltration that were compatible with autoimmune hepatitis. Then, both patients were started on prednisolone, to which they responded well. Liver biopsy is to be considered for type 1 diabetes patients if there is no improvement of liver dysfunction after discontinuation of statins.
Keyphrases
- cardiovascular disease
- end stage renal disease
- type diabetes
- newly diagnosed
- ejection fraction
- chronic kidney disease
- multiple sclerosis
- prognostic factors
- coronary artery disease
- case report
- mesenchymal stem cells
- single cell
- patient reported outcomes
- drug induced
- skeletal muscle
- insulin resistance
- metabolic syndrome
- weight loss